arrow
Ε

Εleftherios Ζervas

athens chest hospital
H指数:23
被引数:2,334

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives

关于肺癌筛查的构建性叙事综述:来自多学科工作组及患者代表的当前证据、临床实践意义和实施见解

2025-10-010
PRE
Newly diagnosed eosinophilic granulomatosis with polyangiitis in patients on biologics for severe asthma: A multicenter case series

新诊断的嗜酸性肉芽肿性多血管炎在生物制剂治疗重症哮喘患者中的多中心病例系列

2025-04-150
PRE
T2-low severe asthma clinical spectrum and impact: The Greek PHOLLOW cross-sectional study

T2-low重症哮喘临床谱及影响:希腊PHOLLOW横断面研究

2025-01-290
OAAI
Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study

重度嗜酸性哮喘患者接受美泊利单抗治疗后的临床缓解:RELight研究的事后分析

2025-01-011
PRE
Characteristics of severe asthma patients requiring ICU treatment across the SHARP CRC
2024-10-300
PRE
Initial data analysis of the SHARP CRC patient population reveals a large heterogeneity among European patients with severe asthma
2024-10-300
PRE
Multimorbidity burden in severe asthma across the SHARP CRC
2024-10-300
PRE
Clinical characteristics of severe asthma patients in Europe, according to the percentage of GDP spent on healthcare- a SHARP-CRC study
2024-10-300
PRE
The REALISM Study: The Experience of Pulmonologists with Benralizumab in Greece
2024-10-300
PRE
Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study
2024-10-300
PRE
Oral corticosteroids and biologics use in the Greek Severe Asthma Registry (GSAR)
2024-10-300
PRE
Characteristics of never-, switching, and persisting users of biologics for severe asthma - SHARP-CRC study
2024-10-300
PRE
Severe Asthma Multimorbidity Clusters Across Europe; Findings From SHARP
2024-10-300
PRE
Heterogeneity of comorbidities captured by European national severe asthma registries in SHARP CRC
2024-10-300
PRE
Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study
2023-12-120
PRE
The clinical experience of patients with severe asthma and previous treatment with omalizumab, choosing mepolizumab in Greece.
2023-10-270
PRE
Follow-up of patients with severe eosinophilic asthma receiving benralizumab for one year (gReek rEAl Life regIStry of benralizuMab: REALISM Study)
2023-10-270
PRE